Urotensin I (Catostomus urotensin I) TFA, a CRF-like neuropeptide, acts as an agonist of CRF receptor with pEC50s of 11.46, 9.36 and 9.85 for human CRF1, human CRF2 and rat CRF2α receptors in CHO cells, and Kis of 0.4, 1.8, and 5.7 nM for hCRF1, rCRF2α and mCRF2β receptors, respectively.

c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM. c-Fms-IN-10 has anti-tumor activity.

gamma-Secretase Modulators (Amyloid-β production) is a Amyloid-β production.

TML-6 inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 upregulates Apo E and suppresses NF-κB, mTOR. TML-6 increases the activity of the anti-oxidative Nrf2 gene. TML-6, an orally active curcumin derivative, has the potential for Alzheimer’s disease (AD) research.

CJ-2360 is a potent and orally active ALK with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potenty activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated.

Fmoc-D-Val-D-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).

Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).

Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-drug-conjugation (ADC).

Cyanine5 NHS ester iodide is a red emitting fluorescent dye for labeling of amino-groups in peptides, proteins, and oligonucleotides.

PROTAC IDO1 Degrader-1 is the first potent IDO1 (indoleamine 2,3-dioxygenase 1) degrader that hijacks IDO1 to CRBN E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC50=2.84 μM). PROTAC IDO1 Degrader-1 moderately improves the tumor-killing activity of H ER2 CAR-T cells.

CP5V is a PROTAC, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation.

Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

LY-411575 isomer 2 is an isomer of LY411575, which is a potent γ-secretase.

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase, which inhibits Aurora C, Aurora B, and Aurora A with IC50s of 1 nM, 7 nM, 120 nM, respectively. Ilorasertib also suppresses RET tyrosine kinase, PDGFRβ and Flt1 with IC50s of 7 nM, 3 nM and 32 nM, respectively.

SU5204, a tyrosine kinase extracted from patent US5792783A, has IC50s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively.

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.

Syk-IN-4 is a potent, selective and orally bioavailable SYK with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.

EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants.

IBT6A hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM.

IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk with an IC50 of 0.5 nM.

ML786 dihydrochloride potent and orally bioavailable Raf, with IC50s of 2.1, 4.2, and 2.5 nM for V600EΔB-Raf, wt B-Raf, and C-Raf, respectively. ML786 dihydrochloride also inhibits Abl-1, DDR2, EPHA2, KDR, and RET (IC50=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 dihydrochloride can be used for the research of cancers.

PI3Kδ-IN-8 is a potent, selective and orally active PI3Kδ, with an IC50 of 3.3 nM. PI3Kδ-IN-8 shows selectivity for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC50=377.2, 241.6, 17.9 nM, respectively). PI3Kδ-IN-8 has anti-tumor activity.

Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC50 of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II.

Isomaltotetraose is one of isomalto-oligosaccharide (IMO), the main hydrolysis end products of DexKQ. Isomaltotetraose can induce dextranase synthesis.

Hydroxylapatite (Hydroxyapatite) is a naturally occurring calcium phosphate which is a major mineral component of bone and teeth bones. Nano-scale Hydroxylapatite particles are increasingly being used as carriers for controlled and targeted delivery of bioactive agents like drugs, proteins, and nucleic acids due to their high porosity, negative charge, and biodegradability .

D-Saccharic acid potassium salt (D-Glucaric acid potassium, Potassium bisaccharate) is an endogenous metabolite.

Sodium mesoxalate monohydrate (sodium 2,2-dihydroxymalonate) is an endogenous metabolite.

Thiamine monophosphate chloride dihydrat (Vitamin B1 Monophosphate Chloride, Sineurina, Phosphothiamine) is an endogenous metabolite.

Dihydroxyfumaric acid hydrate (DHF) is an endogenous metabolite. The diester derivative of dihydroxyfumaric acid hydrate (DHF) has been used exclusively as an electrophile in organic synthesis.

Nα-Acetyl-L-asparagine (N-Acetylasparagine, (S)-2-acetamido-4-amino-4-oxobutanoic acid) is an endogenous metabolite that exists in human brain.